Caggiano Anthony 4

What Happened
Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics (CGTX), was granted 400,000 restricted stock units (RSUs) on Feb 3, 2026. To cover tax withholding tied to the vesting/settlement, the issuer withheld 11,488 shares on Feb 3 at $1.12 ($12,867) and 26,919 shares on Feb 4 at $1.03 ($27,727), for a total of 38,407 shares withheld (~$40,594). The RSU grant itself had no exercise price (reported $0.00) and is an award rather than an open-market purchase.

Key Details

• Transaction types: A = Award/Grant (400,000 RSUs on 2026-02-03); F = Shares withheld for tax withholding (11,488 @ $1.12 on 2026-02-03; 26,919 @ $1.03 on 2026-02-04).
• Withheld total: 38,407 shares; cash value withheld reported ≈ $40,594. Net shares expected upon settlement: 400,000 − 38,407 = 361,593.
• Footnotes: F1 — each RSU is a contingent right to one share upon settlement; F2 — withheld shares were used to satisfy tax withholding obligations.
• Filing/timeliness: Form 4 filed 2026-02-05 for transactions on 2026-02-03–02-04; this filing appears timely (filed within the Form 4 two-business-day window).
• Shares owned after transaction: not specified in the information provided.

Context
RSU grants are compensation awards and are common for executives; withholding shares to cover taxes is a routine administrative step (not a market sale). This filing documents an award and associated tax-withholding disposition — not a purchase or open-market sale.